Edesa Biotech (NASDAQ:EDSA)’s stock price shot up 2.5% during trading on Monday . The stock traded as high as $3.28 and last traded at $3.27, 34,583 shares changed hands during trading. An increase of 7% from the average session volume of 32,205 shares. The stock had previously closed at $3.19.
The stock’s 50 day simple moving average is $3.41.
Edesa Biotech (NASDAQ:EDSA) last announced its quarterly earnings data on Thursday, December 12th. The company reported ($0.07) earnings per share (EPS) for the quarter. Edesa Biotech had a negative net margin of 785.02% and a negative return on equity of 80.11%. The business had revenue of $0.41 million during the quarter.
In other Edesa Biotech news, Director Der Velden Peter Van acquired 140,625 shares of the company’s stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $3.20 per share, for a total transaction of $450,000.00. Following the purchase, the director now owns 8,524 shares in the company, valued at approximately $27,276.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 66.00% of the company’s stock.
An institutional investor recently raised its position in Edesa Biotech stock. Renaissance Technologies LLC increased its position in shares of Edesa Biotech (NASDAQ:EDSA) by 59.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,073 shares of the company’s stock after purchasing an additional 9,320 shares during the quarter. Renaissance Technologies LLC owned approximately 0.33% of Edesa Biotech worth $103,000 at the end of the most recent quarter. Institutional investors own 0.32% of the company’s stock.
Edesa Biotech Company Profile (NASDAQ:EDSA)
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. The company was founded in 2015 and is headquartered in Markham, Canada.
